Literature DB >> 11159623

Thiazolidinediones for type 2 diabetes. All glitazones may exacerbate heart failure.

A Benbow, M Stewart, G Yeoman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11159623

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  12 in total

1.  Prescribing of rosiglitazone and pioglitazone following safety signals: analysis of trends in dispensing patterns in the Netherlands from 1998 to 2008.

Authors:  Rikje Ruiter; Loes E Visser; Myrthe P P van Herk-Sukel; Petronella H Geelhoed-Duijvestijn; Sandra de Bie; Sabine M J M Straus; Peter G M Mol; Silvana A Romio; Ron M C Herings; Bruno H Ch Stricker
Journal:  Drug Saf       Date:  2012-06-01       Impact factor: 5.606

Review 2.  After avandia: the use of antidiabetic drugs in patients with heart failure.

Authors:  Khaled I Khalaf; Heinrich Taegtmeyer
Journal:  Tex Heart Inst J       Date:  2012

3.  Insulin sensitizers and heart failure: an engine flooded with fuel.

Authors:  Khaled I Khalaf; Heinrich Taegtmeyer
Journal:  Curr Hypertens Rep       Date:  2010-12       Impact factor: 5.369

4.  Metformin in Diabetic Patients with Heart Failure: Safe and Effective?

Authors:  Ijeoma Ananaba Ekeruo; Amirreza Solhpour; Heinrich Taegtmeyer
Journal:  Curr Cardiovasc Risk Rep       Date:  2013-12-01

5.  Cardiovascular safety of dipeptidyl peptidase-4 inhibitors: recent evidence on heart failure.

Authors:  Saumya Reddy Kankanala; Rafay Syed; Quan Gong; Boxu Ren; Xiaoquan Rao; Jixin Zhong
Journal:  Am J Transl Res       Date:  2016-05-15       Impact factor: 4.060

Review 6.  The role of the angiotensin system in cardiac glucose homeostasis: therapeutic implications.

Authors:  Elena Bernobich; Luisa de Angelis; Carlos Lerin; Giuseppe Bellini
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 7.  The role of sulphonylureas in the management of type 2 diabetes mellitus.

Authors:  Marc Rendell
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 8.  Combined thiazolidinedione-insulin therapy: should we be concerned about safety?

Authors:  André J Scheen
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

9.  Idealized PPARγ-Based Therapies: Lessons from Bench and Bedside.

Authors:  Angélica Amorim Amato; Francisco de Assis Rocha Neves
Journal:  PPAR Res       Date:  2012-06-14       Impact factor: 4.964

Review 10.  Thiazolidinediones and Edema: Recent Advances in the Pathogenesis of Thiazolidinediones-Induced Renal Sodium Retention.

Authors:  Shoko Horita; Motonobu Nakamura; Nobuhiko Satoh; Masashi Suzuki; George Seki
Journal:  PPAR Res       Date:  2015-05-14       Impact factor: 4.964
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.